Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

13.86
EUR
+0.12
(+0.87%)
0.12EPS
130.48P/E
1.73BMarket Cap
Mar 03Next Earn

Total Valuation

EUR

As of September 30, 2026, Sarepta Therapeutics, Inc. carries a market capitalization of 1.73B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.73B
Enterprise Value1.88B

Important Dates

Sarepta Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of September 30, 2026, Sarepta Therapeutics, Inc. has 107.23M shares outstanding.

Shares Outstanding107.23M

Valuation Ratios

As of September 30, 2026, Sarepta Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 130.48. The price-to-sales ratio is 0.98, and the price-to-book ratio stands at 1.28.

PE Ratio130.48
PS Ratio0.98
PB Ratio1.28
P/TBV Ratio1.31
P/FCF Ratio11.64
P/OCF Ratio10.38

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Sarepta Therapeutics, Inc. trades at an EV/FCF ratio of 10.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.88B versus a market cap of 1.73B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.09
EV / FCF10.37

Financial Position

As of September 30, 2026, Sarepta Therapeutics, Inc. maintains a current ratio of 3.46, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.88, indicating elevated leverage, while an interest coverage ratio of -0.20 demonstrates limited ability to service its debt obligations.

Current Ratio3.46
Quick Ratio1.99
Debt / Equity68.88
Debt / EBITDA-62.89
Interest Coverage-0.20

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. posted a return on equity (ROE) of 1.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.75, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.89, useful for judging operating efficiency across full business cycles. The company generates approximately 2.07M in revenue per employee across its workforce of 835.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Sarepta Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)1.04
Return on Assets (ROA)0.44
Return on Invested Capital (ROIC)-0.75
Return on Capital Employed (ROCE)1.89
Revenue Per Employee2.07M
Employee Count835.00
Inventory Turnover0.87

Taxes

EUR

Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. recorded 19.94M in income tax expense. That works out to an effective tax rate of 60.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.97M, leaving 13.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax19.94M
Effective Tax Rate60.49

Stock Price Statistics

EUR

As of the close on November 17, 2026, Sarepta Therapeutics, Inc.'s stock has declined approximately 8.27% over the past 52 weeks. The 50-day moving average sits at 16.25, while the 200-day moving average is 16.00.

52-Week Price Change-8.27%
50-Day Moving Average16.25
200-Day Moving Average16.00

Income Statement

EUR

Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. generated 1.73B in revenue and converted that into 13.02M in net income, yielding earnings per share of 0.12. EBITDA reached -14.77M, while operating income came in at -7.41M.

Revenue1.73B
Gross Profit980.21M
Operating Income-7.41M
Pretax Income32.97M
Net Income13.02M
EBITDA-14.77M
EBIT-43.14M
Earnings Per Share (EPS)0.12

Balance Sheet

EUR

As of September 30, 2026, Sarepta Therapeutics, Inc. holds 775.34M in cash and equivalents against 929.09M in total debt, resulting in a net debt position of 339.34M. Total book value stands at 1.35B, with working capital of 1.43B providing operational flexibility.

Cash & Cash Equivalents775.34M
Total Debt929.09M
Net Debt339.34M
Equity (Book Value)1.35B
Book Value Per Share12.58
Working Capital1.43B

Cash Flow

EUR

Sarepta Therapeutics, Inc. produced 163.72M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -11.91M in capital expenditures, free cash flow totaled 151.81M - equivalent to 1.44 per share.

Operating Cash Flow163.72M
Capital Expenditures-11.91M
Free Cash Flow151.81M
FCF Per Share1.44

Margins

Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. posted a gross margin of 56.79, reflecting its pricing power and cost economics. The operating margin of -0.43 and net profit margin of 0.75 provide insight into operational efficiency.

Gross Margin56.79
Operating Margin-0.43
Pretax Margin1.91
Profit Margin0.75
EBITDA Margin-0.86

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 8.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sarepta Therapeutics, Inc. shareholders.

Shareholder Yield1.99
FCF Yield8.59

Stock Splits

Sarepta Therapeutics, Inc.'s most recent stock split took place on July 12, 2012 with a 6:1 split ratio.

Last Split Date7/12/2012
Split Ratio6:1

Scores

As of September 30, 2026, Sarepta Therapeutics, Inc. has an Altman Z-Score of -0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.09